Recent Share Transactions by Bavarian Nordic Executives
COPENHAGEN, Denmark – Bavarian Nordic A/S (OMX: BAVA) has revealed significant share transactions involving its executives and their closely associated parties. These transactions reflect the company's commitment to effective management and maintaining regulatory transparency.
Details of the Executives Involved in Transactions
Recently, it was reported that Paul John Chaplin, the President and Chief Executive Officer of Bavarian Nordic, participated in transactions related to the sale of shares. This activity followed the exercise of warrants that were granted to the executive team as part of incentive programs established in 2019 and 2020. Such sales are often necessary for executives to meet tax obligations arising from their earnings through equity compensation.
Purpose Behind the Share Sales
As a result of these transactions, the net holdings of shares for the involved executives have increased. The transactions primarily consisted of share sales at an average price of DKK 243.8027 per share, with a considerable volume sold to cover the taxable income generated from the exercise of previous warrants.
Execution of Transactions
The reported transactions were executed at Nasdaq Copenhagen A/S. For example, on one particular day, Chaplin sold a total of 98,855 shares, resulting in a transaction value exceeding DKK 24.1 million. Other executives, including Henrik Juuel and Jean-Christophe May, also participated in similar transactions, enhancing their portfolios while addressing their tax responsibilities.
Aggregate Information from Recent Transactions
Overall, executives sold a substantial number of shares across multiple transactions on the same date. For instance, Juuel sold 34,416 shares, which amounted to over DKK 8.39 million, while May executed a transaction involving 7,039 shares valued at around DKK 1.71 million. These transactions highlight the proactive financial strategies employed by Bavarian Nordic’s leadership to optimize their holdings while ensuring compliance with tax laws.
About Bavarian Nordic A/S
Bavarian Nordic is a fully integrated vaccine company focused on protecting lives through innovative vaccine solutions. The company is recognized as a global leader in smallpox and mpox vaccines, which are supplied to governments around the world. Additionally, Bavarian Nordic has a strong portfolio of vaccines that address various traveler and endemic diseases. Through its dedication to public health, the company continues to make significant advancements in the vaccine sector.
Contact Information
For any inquiries, Rolf Sass Sørensen, Vice President of Investor Relations, can be reached at rss@bavarian-nordic.com or by phone at +45 61 77 47 43. In the United States, Graham Morrell at Paddock Circle Advisors is available at graham@paddockcircle.com or +1 781 686 9600.
Frequently Asked Questions
What recent share transactions occurred at Bavarian Nordic?
Executives at Bavarian Nordic have recently sold shares following the exercise of warrants linked to incentive programs from previous years.
Why are executives selling shares?
The primary reason for the sales is to cover tax obligations that arise from the exercised warrants.
What is the average sale price of shares sold?
The shares were sold at an average price of DKK 243.8027 each.
Where were these transactions conducted?
All transactions were carried out at Nasdaq Copenhagen A/S.
Who can be contacted for more information?
For investor relations inquiries, Rolf Sass Sørensen is the contact person, and he is available via email or phone.
